Mirtazapine in Alzheimer-associated Weight Loss

Brugmann University Hospital22 enrolled

Overview

Weight loss is a frequent problem associated with Alzheimers disease (AD). Mirtazapine has weight loss as a frequent side effect. The aim of this retrospective study is to check whether mirtazapine 30 mg (once daily) can counteract weight loss in patients with AD or mixed dementia (AD + vascular).

Study Type

OBSERVATIONAL

Enrollment

Conditions

Alzheimer's Disease Weight Loss Mixed Dementia Dementia

Interventions

mirtazapineDRUG

30 mg at bedtime

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * AD or mixed dementia * documented weight loss * mirtazapine 30 mg explicitly prescribed against weight loss Exclusion Criteria: * no treatment compliance * other causes of weight loss * other interventions against weight loss

Locations (1)

CHU Brugmann

Brussels, Belgium

Outcomes

Primary Outcomes

body weight

Time frame: 6 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.